Horizon Therapeutics Public Limited Company (HZNP) Plunges 5.58% on September 24

Equities Staff  |

Horizon Therapeutics Public Limited Company (HZNP) had a rough trading day for Thursday September 24 as shares tumbled 5.58%, or a loss of $-4.45 per share, to close at $75.33. After opening the day at $79.00, shares of Horizon Therapeutics Public Limited Company traded as high as $79.21 and as low as $73.88. Volume was 2.22 million shares over 31,523 trades, against an average daily volume of n/a shares and a total float of 220.35 million.

As a result of the decline, Horizon Therapeutics Public Limited Company now has a market cap of $16.6 billion. In the last year, shares of Horizon Therapeutics Public Limited Company have traded between a range of $82.60 and $23.81, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

For a complete fundamental analysis of Horizon Therapeutics Public Limited Company, check out Equities.com’s Stock Valuation Analysis report for HZNP.

Still paying commissions on stock trades? Equities.com now offers $7.99/month unlimited trading and flat-fee options trading for $89.99/month! Get started today by https://www.equities.com/trading-start

Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.

Horizon Therapeutics Public Limited Company is based out of Dublin 4, and has some 1,225 employees. Its CEO is Timothy P. Walbert.

Horizon Therapeutics Public Limited Company is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Horizon Therapeutics Public Limited Company and to follow the company’s latest updates, you can visit the company’s profile page here: HZNP’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change